{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:29:36Z","timestamp":1793816976764,"version":"4.6.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Recessive dystrophic epidermolysis bullosa (RDEB) is a life-limiting collagen type VII alpha-1 (COL7A1)-related disorder characterized by skin fragility, chronic wounds, and early mortality. Gene therapies aim to restore collagen type VII (C7) expression and improve wound healing, but clinical evidence remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To synthesize current evidence on the safety and effectiveness of gene therapy approaches for RDEB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we searched major databases through 7 March 2025 for interventional studies evaluating gene therapies in RDEB. Two reviewers independently performed study selection, data extraction, and risk-of-bias assessment. Given the substantial heterogeneity, findings were synthesized narratively without meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Five clinical trials met the inclusion criteria and evaluated\n                      <jats:italic toggle=\"yes\">ex vivo<\/jats:italic>\n                      autologous cell-based therapies and\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      topical vector delivery. Topical herpes simplex virus type 1-based COL7A1 therapy achieved a significantly higher rate of complete wound closure than controls (71% versus 20% at 3\u00a0months;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001).\n                      <jats:italic toggle=\"yes\">Ex vivo<\/jats:italic>\n                      epithelial grafting demonstrated durable clinical benefit during long-term follow-up. Molecular analyses generally showed restoration or increased C7 expression. Patient-reported outcomes improved alongside sustained wound healing. Treatments were generally well tolerated, with predominantly mild adverse events, no treatment-related serious safety signals, and evidence of immunologic tolerance to recombinant C7.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Gene therapy for RDEB demonstrates a favorable early safety profile and promising efficacy. However, the small number of heterogeneous early-phase trials and limited follow-up preclude definitive conclusions. Larger, rigorously designed studies with extended follow-up are required to confirm long-term safety and clinical effectiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000005683","type":"journal-article","created":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:00:12Z","timestamp":1793815212000},"page":"6718-6729","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Emerging gene therapies in the treatment of recessive dystrophic epidermolysis bullosa: a systematic review"],"prefix":"10.1097","volume":"88","author":[{"given":"Abolfazl","family":"Nikkhoy","sequence":"first","affiliation":[{"name":"Student Research Committee, Guilan University of Medical Sciences, Rasht, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6240-2756","authenticated-orcid":false,"given":"Amirhossein","family":"Larijani","sequence":"additional","affiliation":[{"name":"Student Research Committee, Guilan University of Medical Sciences, Rasht, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erfan","family":"Rajabi","sequence":"additional","affiliation":[{"name":"Student Research Committee, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-5551","authenticated-orcid":false,"given":"Hojat","family":"Eftekhari","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Skin Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"R1-20261104","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s13023-022-02546-9","article-title":"Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa","volume":"17","author":"So","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"10270","DOI":"10.3390\/ijms251910270","article-title":"Current status of biomedical products for gene and cell therapy of recessive dystrophic epidermolysis bullosa","volume":"25","author":"Zorina","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"780\u201388","DOI":"10.1038\/s41591-022-01737-y","article-title":"In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial","volume":"28","author":"Gurevich","year":"2022","journal-title":"Nat Med"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"e130554","DOI":"10.1172\/jci.insight.130554","article-title":"Phase 1\/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa","volume":"4","author":"Eichstadt","year":"2019","journal-title":"JCI Insight"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13023-021-01811-7","article-title":"A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa","volume":"16","author":"Tang","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"96\u2013108","DOI":"10.1016\/j.omtm.2022.09.005","article-title":"Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by in vivo CRISPR-Cas9 delivery using adenoviral vectors","volume":"27","author":"Garc\u00eda","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"R7-20261104","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/bioengineering10040422","article-title":"Stem cell therapies for epidermolysis bullosa treatment","volume":"10","author":"Niti","year":"2023","journal-title":"Bioengineering"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.3390\/ijms25042243","article-title":"Emerging gene therapeutics for epidermolysis bullosa under development","volume":"25","author":"Bischof","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R9-20261104","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R10-20261104","doi-asserted-by":"crossref","first-page":"i4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R11-20261104","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R12-20261104","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"R13-20261104","doi-asserted-by":"crossref","first-page":"e126243","DOI":"10.1172\/jci.insight.126243","article-title":"Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa","volume":"4","author":"Lwin","year":"2019","journal-title":"JCI Insight"},{"key":"R14-20261104","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.jid.2019.03.1155","article-title":"Cultured epidermal autografts from clinically revertant skin as a potential wound treatment for recessive dystrophic epidermolysis bullosa","volume":"139","author":"Matsumura","year":"2019","journal-title":"J Investig Dermatol"},{"key":"R15-20261104","doi-asserted-by":"crossref","first-page":"2211\u201319","DOI":"10.1056\/NEJMoa2206663","article-title":"Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa","volume":"387","author":"Guide","year":"2022","journal-title":"N Engl J Med"},{"key":"R16-20261104","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13023-025-03635-1","article-title":"Taking care of patients with recessive dystrophic epidermolysis bullosa from birth to adulthood: a multidisciplinary Italian Delphi consensus","volume":"20","author":"El Hachem","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"R17-20261104","doi-asserted-by":"crossref","first-page":"987\u201392","DOI":"10.1038\/mt.2015.47","article-title":"From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa","volume":"23","author":"Webber","year":"2015","journal-title":"Mol Ther"},{"key":"R18-20261104","doi-asserted-by":"crossref","first-page":"101134","DOI":"10.1016\/j.omtm.2023.101134","article-title":"CRISPR-Cas9-based non-viral gene editing therapy for topical treatment of recessive dystrophic epidermolysis bullosa","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"R19-20261104","doi-asserted-by":"crossref","first-page":"2059\u201375","DOI":"10.1007\/s13555-024-01227-8","article-title":"Treatment of epidermolysis bullosa and future directions: a review","volume":"14","author":"Danescu","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R20-20261104","doi-asserted-by":"crossref","first-page":"115294","DOI":"10.1016\/j.addr.2024.115294","article-title":"Challenges and progress related to gene editing in rare skin diseases","volume":"208","author":"Hofbauer","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"R21-20261104","doi-asserted-by":"crossref","first-page":"e20220046","DOI":"10.1590\/1678-4685-gmb-2022-0046","article-title":"Protection is not always a good thing: the immune system\u2019s impact on gene therapy","volume":"45","author":"Freitas","year":"2022","journal-title":"Genet Mol Biol"},{"key":"R22-20261104","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"R23-20261104","doi-asserted-by":"crossref","first-page":"105834","DOI":"10.1016\/j.ebiom.2025.105834","article-title":"Viral and non-viral vectors in gene therapy: current state and clinical perspectives","volume":"118","author":"Geng","year":"2025","journal-title":"eBioMedicine"},{"key":"R24-20261104","doi-asserted-by":"crossref","first-page":"699597","DOI":"10.3389\/fcell.2021.699597","article-title":"The potential of CRISPR\/Cas9 gene editing as a treatment strategy for inherited diseases","volume":"9","author":"Abdelnour","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"R25-20261104","doi-asserted-by":"crossref","first-page":"2402630","DOI":"10.1002\/adfm.202402630","article-title":"Exploring the potential and challenges of CRISPR delivery and therapeutics for genetic disease treatment","volume":"34","author":"Yang","year":"2024","journal-title":"Adv Funct Mater"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:00:15Z","timestamp":1793815215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000005683","relation":{},"ISSN":["2049-0801","2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"},{"value":"2049-0801","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"2026-02-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}